See more : Orion Oyj (ORNAV.HE) Income Statement Analysis – Financial Results
Complete financial analysis of Vor Biopharma Inc. (VOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vor Biopharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Element 25 Limited (ELMTF) Income Statement Analysis – Financial Results
- Sunac China Holdings Limited (SCCCF) Income Statement Analysis – Financial Results
- Tesgas S.A. (TSG.WA) Income Statement Analysis – Financial Results
- Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L) Income Statement Analysis – Financial Results
- Triton International Limited (TRTN-PA) Income Statement Analysis – Financial Results
Vor Biopharma Inc. (VOR)
About Vor Biopharma Inc.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 3.49M | 8.96M | 4.45M | 1.39M | 91.00K | 20.00K |
Gross Profit | -3.49M | -8.96M | -4.45M | -1.39M | -91.00K | -20.00K |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 94.32M | 64.55M | 47.53M | 31.62M | 6.20M | 2.43M |
General & Administrative | 31.72M | 28.87M | 21.49M | 11.75M | 4.22M | 427.00K |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 31.72M | 28.87M | 21.49M | 11.75M | 4.22M | 427.00K |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 126.04M | 93.42M | 69.02M | 43.37M | 10.42M | 2.86M |
Cost & Expenses | 126.04M | 93.42M | 69.02M | 43.37M | 10.42M | 2.86M |
Interest Income | 8.17M | 1.32M | 119.00K | 29.00K | 154.00K | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 608.00K | 1.00M |
Depreciation & Amortization | 3.49M | 8.96M | 4.45M | 1.39M | 91.00K | 20.00K |
EBITDA | -114.37M | -90.89M | -67.58M | -41.95M | -10.17M | -2.84M |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -126.04M | -93.42M | -69.02M | -43.37M | -10.42M | -2.86M |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 8.17M | 1.32M | 119.00K | 29.00K | -422.00K | -1.29M |
Income Before Tax | -117.86M | -92.09M | -68.90M | -43.34M | -10.84M | -4.15M |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | -1.32M | -119.00K | 427.70K | 608.00K | -289.00K |
Net Income | -117.86M | -90.77M | -68.78M | -43.34M | -11.45M | -4.15M |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -1.75 | -2.29 | -1.85 | -1.17 | -0.31 | -0.73 |
EPS Diluted | -1.75 | -2.29 | -1.85 | -1.17 | -0.31 | -0.73 |
Weighted Avg Shares Out | 67.19M | 39.55M | 37.17M | 37.13M | 37.12M | 5.66M |
Weighted Avg Shares Out (Dil) | 67.19M | 39.55M | 37.17M | 37.13M | 37.12M | 5.66M |
YouHodler stellt auf der 2023 Crypto Valley Conference bahnbrechende B2B-Fintech-Lösungen vor
Q4 Inc. lanciert Earnings Lifecycle auf der Q4-Plattform
Visa plant neues globales Technologie- und Produktdrehkreuz in Polen zur Unterstützung des 24/7-Entwicklungsmodells für Innovation
Cvent präsentiert die Top-Tagungsziele und Top-Tagungshotels in Europa für 2023
ADVA Optical Networking SE kündigt geplanten CEO-Wechsel an
Airship-Studie: Die meisten Verbraucher nutzen mobile Apps, um sich das Leben zu erleichtern
Vecima und Witke stellen Remote-MACPHY-Lösung für Telenet Systems Österreich bereit
Vor Bio to Participate in Upcoming Investor Conferences
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%
Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells
Source: https://incomestatements.info
Category: Stock Reports